Cigna to Support Cleerly's AI Cardiovascular Imaging Solutions

Cigna (CI) has approved coverage for Cleerly's AI-powered cardiovascular imaging technology, joining UnitedHealthcare and EviCore, a strategic move leveraging AI for more accurate arterial plaque detection and earlier identification of high-risk patients. This decision, supported by Medicare's 2024 coverage and a 2026 CPT code, signals a broader industry shift towards AI in preventive care and value-based models, aiming to reduce long-term healthcare costs. Cigna's 13% year-over-year revenue growth in H1 2025 underscores its competitive focus, aligning with similar digital health initiatives by competitors like UnitedHealth Group and Humana.

Analysis

Cigna's (CI) decision to provide coverage for Cleerly's AI-powered cardiovascular imaging technology marks a significant strategic step in the managed care sector's shift toward value-based care and digital health integration. By joining UnitedHealthcare and aligning with Medicare's recent coverage decision, Cigna is positioning itself at the forefront of adopting preventative technologies designed to mitigate high-cost medical events. This move is supported by a strong financial backdrop, with Cigna reporting 13% year-over-year revenue growth in the first half of 2025, outpacing the reported growth of competitors like Humana (9.9%) and UnitedHealth's Optum division (5.8%) in the same period. The industry-wide adoption, now covering over 61 million Americans and set to be further standardized with a new CPT code in January 2026, underscores the technology's potential to lower long-term healthcare expenditures and improve patient outcomes, thereby strengthening Cigna's competitive moat and potential for sustained margin performance.

Key Decisions for Investors

• Investors should view Cigna's adoption of AI diagnostics as a validation of its growth strategy, as its superior 13% H1 2025 revenue growth suggests effective execution in the competitive value-based care market.
• It is prudent to monitor the impact of this technology on Cigna's medical loss ratio over the next several quarters, as successful implementation should lead to lower costs for expensive cardiovascular treatments.
• The upcoming CPT code launch in January 2026 is a key industry-wide catalyst; investors should assess how quickly competitors like Elevance Health and Humana integrate similar technologies, which could impact Cigna's early-mover advantage.